

# Jefferson Buendía-a

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8332237/publications.pdf>

Version: 2024-02-01

59  
papers

527  
citations

932766

10  
h-index

839053

18  
g-index

94  
all docs

94  
docs citations

94  
times ranked

508  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of high carbohydrate-rich food intake and severity of asthma exacerbation in children between 2 to 6 years aged. <i>Journal of Asthma</i> , 2023, 60, 412-418.	0.9	2
2	Comparison of three alternatives for the management of moderate asthma in children aged 6â€“11 years: a cost-utility analysis. <i>Journal of Asthma</i> , 2023, 60, 761-768.	0.9	2
3	Cost-utility of use of sputum eosinophil counts to guide management in children with asthma. <i>Journal of Asthma</i> , 2022, 59, 31-37.	0.9	9
4	Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 299-305.	0.7	10
5	Cost-utility of azithromycin in patients with severe asthma. <i>Journal of Asthma</i> , 2022, 59, 2008-2015.	0.9	6
6	Costâ€“effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. <i>Journal of Asthma</i> , 2022, 59, 2016-2023.	0.9	13
7	Budget Impact Analysis of Hypertonic Saline Inhalations for Infant Bronchiolitis: The Colombian National Health System Perspective. <i>Value in Health Regional Issues</i> , 2022, 28, 14-18.	0.5	1
8	Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 575-580.	0.7	7
9	As-Needed Use of Short-Acting Î²2-Agonists Alone Versus As-Needed Use of Short-Acting Î²2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1562-1568.	2.0	2
10	Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis. <i>Journal of Asthma</i> , 2022, , 1-8.	0.9	1
11	Cost Utility of Intermittent Inhaled Corticosteroids in Preschoolers with Viral-Triggered Wheeze. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2022, 35, 36-42.	0.3	3
12	SMART therapy in adolescent and adults patients with moderate persistent asthma: a cost-utility analysis. <i>Journal of Asthma</i> , 2022, 59, 2367-2374.	0.9	7
13	Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source. <i>BMC Pediatrics</i> , 2022, 22, 226.	0.7	2
14	TLR4 Gene Polymorphisms Interaction With Ascaris Infection in Severe RSV Bronchiolitis. <i>Frontiers in Pediatrics</i> , 2022, 10, 876882.	0.9	2
15	Dupilumab in children with moderateâ€“severe asthma: A cost utility analysis. <i>Pediatric Pulmonology</i> , 2022, 57, 2313-2319.	1.0	4
16	Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	3
17	Vitamin A supplementation for the prevention of chronic lung disease in premature infants: A costâ€“utility analysis. <i>Pediatric Pulmonology</i> , 2022, 57, 2511-2517.	1.0	1
18	Costs of Respiratory Syncytial Virus Hospitalizations in Colombia. <i>Pharmacoeconomics - Open</i> , 2021, 5, 71-76.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness analysis of phenotypic-guided versus guidelines-guided bronchodilator therapy in viral bronchiolitis. <i>Pediatric Pulmonology</i> , 2021, 56, 187-195.	1.0	4
20	Disability-adjusted life years for acute bronchiolitis in infants in Colombia. <i>Pan African Medical Journal</i> , 2021, 39, 236.	0.3	2
21	Inappropriate antibiotic prescribing for acute bronchiolitis in Colombia: a predictive model. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 2.	1.1	4
22	Cost of illness of RSV infection in a middle-income tropical country. <i>Turkish Journal of Pediatrics</i> , 2021, 63, 673-682.	0.3	9
23	Risk factors for severe bronchiolitis in Colombia. <i>Tropical Doctor</i> , 2021, 51, 434-437.	0.2	1
24	Budget impact analysis of intravenous magnesium sulfate for treating asthma exacerbations in children. <i>Pediatric Pulmonology</i> , 2021, 56, 2370-2371.	1.0	1
25	Budget impact analysis of surfactant therapy for bronchiolitis in critically ill infants: the Colombian National Health System perspective. <i>BMC Health Services Research</i> , 2021, 21, 334.	0.9	4
26	Budget impact analysis of high-flow nasal cannula for infant bronchiolitis: the Colombian National Health System perspective. <i>Current Medical Research and Opinion</i> , 2021, 37, 1627-1632.	0.9	5
27	Cost utility of fractional exhaled nitric oxide monitoring for the management of children asthma. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 33.	0.6	12
28	Cost-utility of tiotropium for children with severe asthma in patients aged 1-5 years. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1866-1868.	1.1	9
29	Cost-utility of as-needed combination low-dose budesonide-formoterol in adolescents mild asthma. <i>Pediatric Pulmonology</i> , 2021, 56, 3699-3705.	1.0	8
30	The use of ipratropium bromide for treating moderate to severe asthma exacerbations in pediatric patients in an emergency setting: A cost-effectiveness analysis. <i>Pediatric Pulmonology</i> , 2021, 56, 3706-3713.	1.0	1
31	The cost-utility of early use of high-flow nasal cannula in bronchiolitis. <i>Health Economics Review</i> , 2021, 11, 41.	0.8	9
32	Bronchopulmonary dysplasia: Incidence and severity in premature infants born at high altitude. <i>Pediatric Pulmonology</i> , 2021, , .	1.0	1
33	Clinical Manifestations and Outcomes of Respiratory Syncytial Virus Infection in Children Less Than Two Years in Colombia. <i>Indian Pediatrics</i> , 2021, 58, 1091-1092.	0.2	4
34	Clinical Manifestations and Outcomes of Respiratory Syncytial Virus Infection in Children Less Than Two Years in Colombia. <i>Indian Pediatrics</i> , 2021, 58, 1091-1092.	0.2	3
35	Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 398.	0.8	7
36	Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 397.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation. <i>Pharmaceutics</i> , 2020, 12, 898.	2.0	11
38	Disability-adjusted life years for respiratory syncytial virus in children under 2 years. <i>BMC Public Health</i> , 2020, 20, 1679.	1.2	9
39	The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis. <i>BMC Health Services Research</i> , 2020, 20, 1001.	0.9	6
40	The cost-utility of intravenous magnesium sulfate for treating asthma exacerbations in children. <i>Pediatric Pulmonology</i> , 2020, 55, 2610-2616.	1.0	11
41	Social and economic variables related with Paraquat self-poisoning: an ecological study. <i>BMC Public Health</i> , 2020, 20, 404.	1.2	5
42	Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis. <i>Archivos Argentinos De Pediatría</i> , 2019, 117, e466-e472.	0.3	2
43	Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage. <i>BMC Research Notes</i> , 2019, 12, 584.	0.6	7
44	Cost of Illness of Paraquat Poisoning in Colombia. <i>Value in Health Regional Issues</i> , 2019, 20, 110-114.	0.5	4
45	Burden of paraquat poisoning in the department of Antioquia, Colombia. <i>BMC Pharmacology &amp; Toxicology</i> , 2019, 20, 11.	1.0	15
46	Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 401-410.	1.0	12
47	Mioclonías inducidas por salbutamol. <i>Biomedica</i> , 2018, 38, 303-307.	0.3	4
48	IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 2-11.	0.2	34
49	Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. <i>Experimental and Clinical Transplantation</i> , 2015, 13, 441-8.	0.2	1
50	Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 442-447.	1.0	23
51	Una percepción en médicos bogotanos acerca del riesgo de reacciones adversas a grupos de medicamentos de uso común. <i>Biomedica</i> , 2014, 34, .	0.3	7
52	Uso del Registro de Solicitudes de Medicamentos no Incluidos en el Listado de Medicamentos Esenciales como Nueva Fuente de Información en los Sistemas Nacionales de Farmacovigilancia. <i>Value in Health Regional Issues</i> , 2013, 2, 357-360.	0.5	1
53	Costo-Efectividad de la Proteína C Reactiva, Procalcitonina y Escala de Rochester: Tres Estrategias Diagnósticas para la Identificación de Infección Bacteriana Severa en Lactantes Febriles sin Foco. <i>Value in Health Regional Issues</i> , 2013, 2, 375-380.	0.5	12
54	Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia. <i>Biomedica</i> , 2013, 33, 411-7.	0.3	24

#	ARTICLE	IF	CITATIONS
55	Actitudes, conocimientos y creencias del paciente hipertenso respecto a la medicación antihipertensiva. <i>Biomedica</i> , 2012, 32, .	0.3	5
56	Burden and typing of rotavirus group A in Latin America and the Caribbean: systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2011, 21, 89-109.	3.9	73
57	Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2009, 26, 341-349.	0.6	29
58	Occult bacteraemia in children with fever without focus though previously vaccinated against pneumococcus. <i>Tropical Doctor</i> , 0, , 004947552210929.	0.2	0
59	Importance of respiratory syncytial virus as a predictor of hospital length of stay in bronchiolitis. <i>F1000Research</i> , 0, 10, 110.	0.8	0